FY2024 EPS Estimates for Unity Biotechnology, Inc. (NASDAQ:UBX) Lifted by Analyst

Unity Biotechnology, Inc. (NASDAQ:UBX) – Investment analysts at HC Wainwright upped their FY2024 earnings per share estimates for shares of Unity Biotechnology in a research note issued on Tuesday, April 16th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings per share of ($2.42) for the year, up from their previous estimate of ($3.83). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Unity Biotechnology’s current full-year earnings is ($2.66) per share. HC Wainwright also issued estimates for Unity Biotechnology’s FY2025 earnings at ($2.52) EPS, FY2026 earnings at ($1.30) EPS and FY2027 earnings at ($0.29) EPS.

Unity Biotechnology Stock Performance

NASDAQ UBX opened at $1.51 on Thursday. The stock has a market cap of $25.35 million, a P/E ratio of -0.51 and a beta of 0.87. The stock has a 50 day simple moving average of $1.66 and a two-hundred day simple moving average of $1.78. Unity Biotechnology has a fifty-two week low of $1.50 and a fifty-two week high of $3.82.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Arete Wealth Advisors LLC purchased a new position in shares of Unity Biotechnology in the 1st quarter valued at approximately $142,000. Wells Fargo & Company MN raised its stake in Unity Biotechnology by 28,706.0% during the second quarter. Wells Fargo & Company MN now owns 43,497 shares of the company’s stock valued at $111,000 after buying an additional 43,346 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Unity Biotechnology by 123.2% during the first quarter. Dimensional Fund Advisors LP now owns 67,899 shares of the company’s stock valued at $111,000 after buying an additional 37,473 shares during the last quarter. State Street Corp raised its stake in Unity Biotechnology by 21.0% during the second quarter. State Street Corp now owns 130,440 shares of the company’s stock valued at $74,000 after buying an additional 22,600 shares during the last quarter. Finally, Commonwealth Equity Services LLC raised its stake in Unity Biotechnology by 53.1% during the first quarter. Commonwealth Equity Services LLC now owns 24,512 shares of the company’s stock valued at $39,000 after buying an additional 8,499 shares during the last quarter. Hedge funds and other institutional investors own 29.49% of the company’s stock.

Unity Biotechnology Company Profile

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.